Synonym
ES 8891; ES-8891; ES8891;
IUPAC/Chemical Name
(3S,4S)-5-cyclohexyl-N-hexyl-3-hydroxy-4-((S)-2-((S)-2-(2-morpholinoacetamido)-3-(naphthalen-1-yl)propanamido)-3-(thiazol-4-yl)propanamido)pentanamide
InChi Key
SYPWPWUSXPWLKW-ZQWQDMLBSA-N
InChi Code
InChI=1S/C42H60N6O6S/c1-2-3-4-10-18-43-39(50)26-38(49)35(23-30-12-6-5-7-13-30)46-42(53)37(25-33-28-55-29-44-33)47-41(52)36(45-40(51)27-48-19-21-54-22-20-48)24-32-16-11-15-31-14-8-9-17-34(31)32/h8-9,11,14-17,28-30,35-38,49H,2-7,10,12-13,18-27H2,1H3,(H,43,50)(H,45,51)(H,46,53)(H,47,52)/t35-,36-,37-,38-/m0/s1
SMILES Code
CCCCCCNC(C[C@H](O)[C@@H](NC([C@@H](NC([C@@H](NC(CN1CCOCC1)=O)Cc2c3ccccc3ccc2)=O)Cc4ncsc4)=O)CC5CCCCC5)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
777.03
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ii Y, Murakami E, Hiwada K. Effect of renin inhibitor, ES-8891, on renal renin secretion and storage in the marmoset: comparison with captopril. J Hypertens. 1991 Dec;9(12):1119-25. PubMed PMID: 1663967.
2: Kokubu T, Hiwada K, Murakami E, Muneta S, Kitami Y, Salmon PF. ES-8891, an orally active inhibitor of human renin. Hypertension. 1990 Jun;15(6 Pt 2):909-13. PubMed PMID: 2112512.
3: Kitami Y, Hiwada K, Murakami E, Iwata T, Muneta S, Kokubu T. Kidney renin gene expression after renin inhibition in the marmoset. Clin Sci (Lond). 1991 Sep;81(3):387-92. PubMed PMID: 1655341.
4: Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem. 1993 Jun 5;268(16):11617-21. PubMed PMID: 8505294.
5: Rongen GA, Lenders JW, Smits P, Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet. 1995 Jul;29(1):6-14. Review. PubMed PMID: 7586899.
6: Hiwada K. [Renin inhibitors]. Nihon Rinsho. 1992 Apr;50 Suppl:764-9. Review. Japanese. PubMed PMID: 1635264.
